Peptide Initiative

Peptides · Peptide comparison

Angiotensin (1-7) vs BPC-157

The heart-friendly peptide that balances your blood pressure and protects your cardiovascular system

The "Wolverine peptide" known for its remarkable healing properties across tendons, ligaments, muscles, and the gut.

  • Healing & Recovery
  • Healing & Recovery

At a glance

Quick comparison

Dose rangeAngiotensin (1-7)100–100 mcg/kgBPC-157250–500 mcg
FrequencyAngiotensin (1-7)Once dailyBPC-157Once daily
AdministrationAngiotensin (1-7)As directed by healthcare providerBPC-157Subcutaneous injection
Cycle lengthAngiotensin (1-7)Ongoing/indefiniteBPC-1574-6 weeks
Onset speedAngiotensin (1-7)Moderate (1-2 weeks)BPC-157Moderate (1-2 weeks)
Evidence levelAngiotensin (1-7)Moderate human trials (Phase 1-2)BPC-157Strong preclinical (extensive animal studies)

Efficacy

Benefit ratings

Heart Health & Protection

Angiotensin (1-7)82%
BPC-157No recorded rating

Blood Pressure Balance

Angiotensin (1-7)78%
BPC-157No recorded rating

Anti-Inflammatory Support

Angiotensin (1-7)74%
BPC-157No recorded rating

Primary Benefit

Angiotensin (1-7)No recorded rating
BPC-15785%

Secondary Benefit

Angiotensin (1-7)No recorded rating
BPC-15778%

Additional Benefit

Angiotensin (1-7)No recorded rating
BPC-15772%

Technical data

Compound specifications

Angiotensin (1-7)

Molecular formula
C41H62N12O11
Molecular weight
899.02 g/mol
Half-life
Approximately 2-6 hours (varies by route of administration)
Bioavailability
Varies by route of administration
CAS number
25016-41-7

BPC-157

Molecular formula
C62H98N16O22
Molecular weight
1419.53 g/mol
Half-life
4-6 hours
Bioavailability
~100% (subcutaneous)
CAS number
137525-51-0

Protocols

Dosing compared

Angiotensin (1-7)

Subcutaneous

  • 100 mcg/kgOnce daily after each chemotherapy session · Up to 6 chemotherapy cyclesIn a cancer trial, this dose was injected under the skin after chemo to help protect platelet counts. A higher 300 mcg/kg dose was also tested but did not work better. [4]

Intravenous

  • 0.5 mg/kgOnce daily · Up to 10 daysIn a COVID-19 study, the lab-made form (called TXA-127) was given as a daily drip into a vein. No serious drug-related side effects were seen. [5]

BPC-157

Subcutaneous

  • 250 mcgOnce daily · 1-2 weeksA common starting amount in research practice, often injected near the injured area. BPC-157 has no human dose-finding trials, so doses come from animal studies and documented practice [1][2].
  • 250-500 mcgTwice daily · 4-6 weeksCommonly used range for tissue and tendon recovery in research practice [1][3].
  • 500 mcgTwice daily · 6-8 weeksUpper end used in practice for more demanding acute injuries [1][3].

Applications

Best suited for

Angiotensin (1-7)

Cardiovascular health and heart protection
Angiotensin (1-7) is particularly well-suited for individuals focused on cardiovascular health and heart protection. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Blood pressure management and hypertension
Angiotensin (1-7) is particularly well-suited for individuals focused on blood pressure management and hypertension. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Recovery from heart-related conditions
Angiotensin (1-7) is particularly well-suited for individuals focused on recovery from heart-related conditions. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Anti-inflammatory support
Angiotensin (1-7) is particularly well-suited for individuals focused on anti-inflammatory support. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

BPC-157

Tendon and ligament injuries
Sprains, strains, tears, tendinitis - BPC-157 accelerates collagen synthesis and tissue repair [1][7]
Gut healing
IBS, leaky gut, ulcers, inflammatory bowel conditions [1][11] - derived from gastric juice, it has a natural affinity for digestive tissue [3][5]
Muscle injuries
Strains, post-workout recovery, chronic muscle issues - promotes angiogenesis and growth factor expression [8]
Joint problems
Arthritis support, joint pain, cartilage issues - anti-inflammatory and regenerative properties [9][10]
Post-surgical recovery
Accelerating healing after procedures - works systemically to enhance the body's repair mechanisms [2]

Safety profile

Side effects

Angiotensin (1-7)

Common

  • Hypotension (Low Blood Pressure)
  • Dizziness or Lightheadedness
  • Injection Site Reactions
  • Headache

Serious

  • Hyperkalemia (High Potassium)

BPC-157

Common

  • Injection site redness
  • Mild nausea
  • Dizziness

Uncommon

  • Headache
  • Fatigue
  • Hot/cold sensations

Serious

  • Allergic reaction

Research status

Safety & evidence

Angiotensin (1-7)

Evidence level
Moderate human trials (Phase 1-2)
FDA status
Research compound
Safety overview
Angiotensin (1-7) is not FDA-approved. Human data come from small cancer trials: a completed phase I dose-escalation and pharmacokinetic study [6] and a randomized, placebo-controlled phase 2 study alongside chemotherapy that reported no drug-related safety issues [4]. Animal studies suggest potential benefits in hypertension and cardiac remodeling but also reveal risks of hypotension, particularly with concurrent ACE inhibitor or ARB therapy. The peptide's effects on systemic inflammation and immune function in animal models are not validated in humans. Human pharmacokinetic data are limited to the phase I study, which set 400 µg/kg as the recommended dose for its once-daily, 5-day schedule [6].

Contraindications

  • Severe hypotension or uncontrolled low blood pressure
  • Acute myocardial infarction in early stages
  • Concurrent use with certain ACE inhibitors without medical supervision
  • Pregnancy and breastfeeding (insufficient safety data)

BPC-157

Evidence level
Strong preclinical (extensive animal studies)
FDA status
Research compound
Safety overview
BPC-157 is a gastric pentadecapeptide with strong preclinical evidence from extensive animal studies spanning over 25 years of research. Critical limitation: BPC-157 has NOT completed Phase 3 human clinical trials. [5] No FDA approval exists. [4][6] Safety data comes primarily from rat and mouse studies, with only limited Phase 1-2 human data. [4][5] Animal studies show no toxicity at therapeutic doses, but human data is insufficient for regulatory approval. [2][4] The peptide is unregulated, and no standardized manufacturing or quality control requirements exist for research compounds. [6][7] Individual responses may vary significantly, and serious medical supervision is essential before use, particularly if you have gastrointestinal conditions, take medications, or have pre-existing medical conditions.

Contraindications

  • Pregnancy
  • Breastfeeding
  • Active cancer
  • History of cancer

Decision guide

Which is right for you?

Angiotensin (1-7)

Choose Angiotensin (1-7) if…

  • Cardiovascular health and heart protection
  • Blood pressure management and hypertension
  • Recovery from heart-related conditions
  • Anti-inflammatory support

BPC-157

Choose BPC-157 if…

  • Injury recovery
  • Post-surgery healing
  • Chronic pain management
  • Gut health